We randomly assigned 71 patients with active chronic Crohn's disease who were resistant to or intolerant of corticosteroids to treatment with oral cyclosporine (5 to 7.5 mg per kilogram of body weight per day) or placebo for three months. Disease activity was assessed on a clinical grading scale without knowledge of the treatment given. At the end of the treatment period, 22 of the 37 cyclosporine-treated patients (59 percent) had improvement, as compared with 11 of the 34 placebo-treated patients (32 percent) (P = 0.032). During cyclosporine treatment, there was significant improvement in plasma orosomucoid levels (P = 0.0025) and the Crohn's Disease Activity Index (P = 0.00012). The effect of treatment became evident after two weeks. In the subsequent three months, during which the patients were gradually withdrawn from treatment, the improvement continued in 14 of the 37 patients (38 percent) in the cyclosporine group and in 5 of the 34 (15 percent) in the placebo group (P = 0.034). No serious adverse events were observed. We conclude that cyclosporine has a beneficial therapeutic effect in patients with active chronic Crohn's disease and resistance to or intolerance of corticosteroids.
Source Information
Department of Internal Medicine and Gastroenterology C, Herlev University Hospital, Copenhagen, Denmark.
This article has been cited by other articles:
Travis, S P L, Stange, E F, Lemann, M, Oresland, T, Chowers, Y, Forbes, A, D'Haens, G, Kitis, G, Cortot, A, Prantera, C, Marteau, P, Colombel, J-F, Gionchetti, P, Bouhnik, Y, Tiret, E, Kroesen, J, Starlinger, M, Mortensen, N J, for the European Crohn's and Colitis Organisation,
(2006). European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut
55: i16-i35
[Abstract][Full Text]
Rafiee, P., Johnson, C. P., Li, M. S., Ogawa, H., Heidemann, J., Fisher, P. J., Lamirand, T. H., Otterson, M. F., Wilson, K. T., Binion, D. G.
(2002). Cyclosporine A Enhances Leukocyte Binding by Human Intestinal Microvascular Endothelial Cells through Inhibition of p38 MAPK and iNOS. PARADOXICAL PROINFLAMMATORY EFFECT ON THE MICROVASCULAR ENDOTHELIUM. J. Biol. Chem.
277: 35605-35615
[Abstract][Full Text]
Wyllie, R., Sarigol, S.
(1998). The Treatment of Inflammatory Bowel Disease in Children. CLIN PEDIATR
37: 421-425
Targan, S. R., Hanauer, S. B., van Deventer, S. J.H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., Rutgeerts, P. J., The Crohn's Disease cA2 Study Group,
(1997). A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor {alpha} for Crohn's Disease. NEJM
337: 1029-1036
[Abstract][Full Text]
Hanauer, S. B.
(1996). Inflammatory Bowel Disease. NEJM
334: 841-848
[Full Text]
Feagan, B. G., Rochon, J., Fedorak, R. N., Irvine, E. J., Wild, G., Sutherland, L., Steinhart, A. H., Greenberg, G. R., Gillies, R., Hopkins, M., Hanauer, S. B., McDonald, J. W.D., The North American Crohn's Study Group Investigato,
(1995). Methotrexate for the Treatment of Crohn's Disease. NEJM
332: 292-297
[Abstract][Full Text]
Vincent, F., Bensousan, T.-A., Whitmore, S. E., Lichtiger, S.
(1995). Cyclosporine in Severe Ulcerative Colitis. NEJM
332: 127-127
[Full Text]
Lichtiger, S., Present, D. H., Kornbluth, A., Gelernt, I., Bauer, J., Galler, G., Michelassi, F., Hanauer, S.
(1994). Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy. NEJM
330: 1841-1845
[Abstract][Full Text]
Feagan, B. G., McDonald, J., Rochon, J., Laupacis, A., Fedorak, R. N., Kinnear, D., Saibil, F., Groll, A., Archambault, A., Gillies, R., Valberg, B., Irvine, E. J., The Canadian Crohn's Relapse Prevention Trial Inve,
(1994). Low-Dose Cyclosporine for the Treatment of Crohn's Disease. NEJM
330: 1846-1851
[Abstract][Full Text]
(1989). CYCLOSPORINE EFFECTIVE IN CROHN'S DISEASE. JWatch General
1989: 1-1
[Full Text]
